Recently, immune checkpoint inhibitors (ICIs) based on programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1), combined with targeted drugs and local therapies, have advanced the systemic treatment of advanced HCC (59, 60). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.